FIELD: medicine.
SUBSTANCE: method involves administering hormone composition comprising 0.5-3.0 mg of estrogen (estradiol, free or etherified conjugated horse estrogen) and 1.5-3.75 mg of nomegestrol acetate for treating estrogen insufficiency cases and stopping ovulation.
EFFECT: enhanced effectiveness of treatment in menopause period without bleeding.
8 cl, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HORMONAL COMPOSITION BASED ON GESTAGEN AND ESTROGEN AND ITS APPLYING | 2000 |
|
RU2261106C2 |
| HORMONAL SUBSTITUTIONAL THERAPY | 1994 |
|
RU2139056C1 |
| CONTRACEPTIVE MEDICINAL AGENT BASED ON GESTAGEN AND ESTROGEN AND METHOD FOR ITS PREPARING | 2000 |
|
RU2258512C2 |
| AGENT FOR CORRECTING MENSTRUAL IRREGULARITIES, MENOPAUSAL DISORDERS | 2022 |
|
RU2801514C1 |
| DROSPIRENONE FOR HORMONAL REPLACEMENT THERAPY | 2005 |
|
RU2402331C2 |
| DROSPYRENON FOR REPLACEMENT HORMONOTHERAPY | 2001 |
|
RU2275198C2 |
| METHOD OF TREATING BENIGN HYPERPLASTIC PROCESSES OF FEMALE REPRODUCTIVE SYSTEM | 2011 |
|
RU2471485C1 |
| NEW MODES OF APPLICATION OF CONTROLLED CONTRACEPTIVE ADMINISTRATION DEVICES | 2006 |
|
RU2408332C2 |
| AGENT FOR HORMONAL CONTRACEPTION THAT INHIBITS OVULATION | 1992 |
|
RU2091069C1 |
| METHOD FOR ENHANCING OF TESTOSTERONE AND ANALOGOUS STEROID LEVELS IN FEMALES | 2001 |
|
RU2286787C2 |
